The IAS TB/HIV Research Prizes are awarded to:

Slides:

Advertisements

Similar presentations

ART in HIV-Infected Patients with TB: Research Priorities Group II Facilitator: David Cohn Rapporteur: Soumya Swaminathan.

Advertisements

June 2004 HITCH Training Slide Set #3 Special Considerations in Antiretroviral Therapy.

OUR FOCUS: UN POLITICAL DECLARATION TARGET No. 4.

A daily dose of 400 mg efavirenz (EFV) is non-inferior to the standard 600 mg dose: week 48 data from the ENCORE1 study, a randomised, double-blind, placebo.

Tuberculosis incidence and risk factors among adult patients receiving HAART in Senegal: a 7-year cohort study Assane DIOUF et al. IRD/UMR 145 CRCF, CHNU.

TB and HIV: Tightly Linked… and Why We Should Care.

The new guidelines Dr Francois Venter Reproductive Health and HIV Research Unit University of the Witwatersrand Feb 2010.

HIV AND AGING Carol Nawina NYIRENDA PAN AFRICAN POSITIVE WOMENS COALITION (PAPWC) COALITION OF ZAMBIAN WOMEN LIVING WITH HIV.

Late-outcomes of TB-IRIS William Worodria, MBChB, MMed, PhD Senior EDCTP Fellow Infectious Disease Institute, Kampala, Uganda Mulago Hospital & Complex,

Cost-effectiveness of different starting criteria of antiretroviral therapy in Mexico. Caro Y., Colchero A., Valencia A., Bautista-Arredondo S., Sierra.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

9.7 million people on ART by end of

Possible solution: Change testing & care for patients in TB treatment Old system TB patient treated at TB center Referred to VCT center for HIV testing.

2 About HIV: Teaching Tool. About HIV: A teaching tool © 2nd edition 2006 This tool was developed by the François-Xavier Bagnoud Center at the University.

Impact evaluation Evaluate new tools Translate new knowledge into policy and implementation Knowledge gap Program implementation.

Treatment as prevention: a new paradigm for HIV control? Richard Hayes.

Isoniazid preventive therapy for people living with HIV: Public health challenges and implementation issues Peter Godfrey-Faussett UNAIDS (with thanks.

2009 Recommendations for Antiretroviral Therapy in Adults and Adolescents Summary of WHO Rapid Advice December 2009 Source: WHO HIV/AIDS Department.

Hepatitis web study Hepatitis web study Ledipasvir-Sofosbuvir in GT1 or GT4 and HIV Coinfection ION-4 Phase 3 Treatment Naïve and Treatment Experienced.

6 th Biannual Joint HIV Sector Review Meeting Nov 11-13,2014 Ministry of Health and Social Welfare Mwanaisha Nyamkara, NTLP Werner Maokola, NACP Nov 11,

Ukrainian TB mortality assessment 2008: Low HIV awareness and access to ART for TB patients associated with high HIV related TB mortality Presenting author:

Challenges to replacing CD4 testing with viroloigical monitoring Andrew Hill, Pharmacology Research Laboratories, University of Liverpool, UK World AIDS.

TREATMENT OF SERO-DISCORDANT COUPLES: IMPLICATIONS FOR YOUNG PEOPLE JJ KUMWENDA (FRCP-UK)

The Pregnancy Journey Open discussion. HIV and AIDS 2013 Romania Cumulative number people diagnosed with HIV since ,261 (of which 9,946 diagnosed.

Will Drug Resistance Jeopardize the National HIV Drug Resistance Programme? Prof. Tulio de Oliveira Africa Centre for Health and Population Studies, University.

WORLD AIDS DAY Zero new HIV infections Zero discrimination Zero AIDS-related deaths.

Scale up TB/HIV activities in Asia Pacific 8-9Aug09 1 TB/HIV collaborative activities in Thailand Sriprapa Nateniyom, M.D. TB Bureau, Department of Disease.

Diagnostics - More than 100 years old Drugs – Last drug 40 years old Vaccine – Nearly 90 years old Lucica Ditiu Executive Secretary, Stop TB Partnership.

Clinical Science, Treatment and Care

Human Immune Deficiency Virus Infection Dr Huda Taha Sep 2015.

Treatment Regimens for Pulmonary Tuberculosis Caused by Drug- Susceptible Organisms Initial PhaseContinuation Phase RegimenDrugs Interval and Doses (Minimal.

Short-Term Efficacy and Tolerance of ddI, 3TC, EFV regimen Once-Daily in HIV-1–Infected African Children: ANRS (Burkiname). Operational lessons from.

Integration of TB and HIV Care Across Two Time Periods in Three (sub) Districts in South Africa J Sumitani 1,2, S Jed 1,2, S Galagan 2, J Gilvydis 1,2,

Novel Antiretroviral Studies and Strategies

New WHO algorithm to prevent TB deaths in seriously ill patients with HIV Yohhei Hamada TB/HIV and Community Engagement.

IMPAACT 2001 STUDY Mhembere T.P. (B. Pharm (Hons), MPH)

PRESENTED AT THE 9TH IAS CONFERENCE ON HIV SCIENCE - PARIS, FRANCE

The story of Munya* (and us)

How differentiated care supports “Tx all” and Dr

Acceptability of early HIV treatment among South Africa women N Garrett, E Norman, V Asari, N Naicker, N Majola, K Leask, Q Abdool Karim and SS Abdool.

HIV and AIDS The management of HIV and AIDS is an ongoing challenge for Anglo companies operating in countries with a high burden of HIV disease Strategy.

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS Reflate TB): a multicentre, phase 2, non-comparative, open-label,

World Tuberculosis Day 2014

Free State TB Information

Atazanavir + ritonavir vs. Lopinavir-ritonavir CASTLE Study

What’s New in the Perinatal Guidelines

Intensification with INSTI

Adult Guidelines Pretoria, Saturday 17th February 2018

The use of cotrimoxazole prophylaxis in the context of HIV infection

World Tuberculosis Day 2015

Monitoring the implementation of the TB Action Plan for the WHO European Region, 2016–2020 EU/EEA situation in 2016 ECDC Tuberculosis Programme European.

Sunday, 22 July, 07:30-20:00 Room Elicium 1, RAI Amsterdam

"3 by 5" progress December 2005.

HIV Management: An Update on the Latest EACS Guidelines

Statin Selection in Special Patient Populations: A Case Challenge

HIV and prevention challenges among adolescent girls and young women

World Tuberculosis Day 2014

Enablers for nationwide expansion of collaborative TB/HIV activities

Statins and HIV:.

Tuberculosis Global Epidemiology

ANTIRETROVIRAL TREATMENT IN RESOURCE-LIMITED SETTINGS: PROGRESS & CHALLENGES IN SOUTH AFRICA YOGAN PILLAY DEPARTMENT OF HEALTH, SOUTH AFRICA IAS, 2014.

Kevin M De Cock MD CDC Kenya Nairobi, September 21, 2003

Anthony D Harries Ministry of Health, Malawi

Volume 375, Issue 9709, Pages (January 2010)

Introduction to poster session and discussion

Intensification with INSTI

VTE Treatment and Secondary Prevention VTE Treatment Trials Initial Dosing.

for the ANRS Reflate TB2 study group

DSD and TB/HIV services in Zimbabwe

Dolutegravir in PEPFAR

Presentation transcript:

The IAS TB/HIV Research Prizes are awarded to: Justin Jones Nathalie De Castro Lelia Chaisson Anna Mandalakas Jennifer Zelnick Severe adherence challenges in the treatment of multi- and extensively drug resistant tuberculosis and HIV: Electronic dose monitoring and mixed methods to identify and characterize high-risk subpopulations Community-based case finding for tuberculosis & HIV integrated with non-communicable diseases in KwaZulu-Natal, South Africa Virologic efficacy of raltegravir vs. efavirenz-based antiretroviral treatment in HIV1- infected adults with tuberculosis: W48 results of the ANRS 12300 Reflate TB2 trial ART initiation within 8 weeks of TB treatment Leads to superior TB outcomes in ART-naïve children and adolescents living with HIV: Results from six high TB/HIV burden countries CD4 count-based guidelines for tuberculin skin testing and tuberculosis preventive therapy in people living with HIV